Neurogene

NGNE

Market cap $306M

Neurogene has transitioned into a data-driven, registrational-stage company with NGN-401 showing strong safety and efficacy for Rett syndrome. NGNE's disciplined financial management provides a cash runway through Q1 2028, allowing focused investment in its lead asset and minimizing dilution risk. NGN-401's clinical data demonstrate durable, multi-domain functional gains and a favorable safety profile, positioning it as a potential first-in-class therapy.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2025 financial results and highlighted recent corporate updates. “We significantly advanced our NGN-401 gene therapy clinical program for Rett syndrome over the past quarter, culminating in the recent dosing of the first participant in the Embolden registrational trial af.

Neurogene Inc. ( NGNE ) Stifel 2025 Healthcare Conference November 12, 2025 4:40 PM EST Company Participants Rachel McMinn - Founder, Executive Chair & CEO Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Paul Matteis Stifel, Nicolaus & Company, Incorporated, Research Division Thank you very much. Happy to be introducing Rachel McMinn, Founder and CEO of Neurogene, who has some new fresh data to talk us through for NGN-401 in Rett syndrome.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive, updated interim clinical data in the pediatric cohort (ages 4-10 cohort) from its ongoing Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. “Updated interim data from our Phase 1/2 trial of NGN-401 show that all pediatric partici.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden™ registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. NGN-401 has the potential to be a best-in-class and first-in-class gene therapy for Rett syndrome, a neurodevelopmental diso.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 1,185 shares of the Company's common stock to one new employee (the “Inducement Grant”) on November 4, 2025 (the “Grant Date”). The Induceme.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the Company has completed discussions with the U.S. Food and Drug Administration (FDA) on its Embolden™ registrational trial protocol and plans to initiate dosing in the fourth quarter of 2025. In response to strong interest from the Rett syndrome community, the trial is expected to en.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, October 14 at 7:00 a.m. ET A webcast of the fireside chat will be accessible from the Invest.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 9,390 shares of the Company's common stock to four new employees (the “Inducement Grants”) on October 1, 2025 (the “Grant Date”). The Induce.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 47,040 shares of the Company's common stock to six new employees (the “Inducement Grants”) on September 3, 2025 (the “Grant Date”). The Indu.